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Abstract Purpose In the present MEG-study, power
spectral analysis of oscillatory brain activity was used to
compare resting state brain activity in both low-grade gli-
oma (LGG) patients and healthy controls. We hypothesized
that LGG patients show local as well as diffuse slowing of
resting state brain activity compared to healthy controls
and that particularly global slowing correlates with neu-
rocognitive dysfunction. Patient and methods Resting state
MEG recordings were obtained from 17 LGG patients and
17 age-, sex-, and education-matched healthy controls.
Relative spectral power was calculated in the delta, theta,
upper and lower alpha, beta, and gamma frequency band. A
battery of standardized neurocognitive tests measuring 6
neurocognitive domains was administered. Results LGG
patients showed a slowing of the resting state brain activity
when compared to healthy controls. Decrease in relative
power was mainly found in the gamma frequency band in
the bilateral frontocentral MEG regions, whereas an
increase in relative power was found in the theta frequency
band in the left parietal region. An increase of the relative
power in the theta and lower alpha band correlated with
impaired executive functioning, information processing,
and working memory. Conclusion LGG patients are char-
acterized by global slowing of their resting state brain
activity and this slowing phenomenon correlates with the
observed neurocognitive deficits.
Keywords Low-grade glioma  Cognition  MEG 
Power analysis
Introduction
Low–grade glioma (LGG) patients constitute 25% [1] of
the glioma patient population and have a survival of 5–
10 years [2]. The optimal treatment for this patient group is
still a matter of debate [3–5]. The first clinical feature of
this disease is epilepsy in two-third of the patients [1, 4].
The majority of LGG patients also suffer from cognitive
deficits, which tend to have a global character and cannot
only be explained by the tumor localization alone [6, 7].
Higher cognitive functions depend on the integrated
activity of several specialized brain areas. Functional
imaging techniques such as electroencephalography (EEG)
and magnetoencephalography (MEG) are used to charac-
terize oscillatory activity in patients with neurodegenerative
This study was supported by Schering Plough Nederland and the
Kapteijnfonds.
I. Bosma (&)  J. J. Heimans  T. J. Postma  J. C. Reijneveld
Department of Neurology, VU University Medical Center,
De Boelelaan 1117, Amsterdam 1081 HV, The Netherlands
e-mail: i.bosma@vumc.nl
C. J. Stam
Department of Clinical Neurophysiology, VU University
Medical Center, Amsterdam, The Netherlands
L. Douw  M. Klein
Department of Medical Psychology, VU University Medical
Center, Amsterdam, The Netherlands
F. Bartolomei
Department of Clinical Neurophysiology and Epileptology,
Centre Hospitalier Universitaire Timone, Marseille, France
B. W. van Dijk
Magnetoencephalography Center, VU University Medical
Center, Amsterdam, The Netherlands
J. C. Reijneveld
Department of Neurology, Academic Medical Center,
Amsterdam, The Netherlands
123
J Neurooncol (2008) 88:77–85
DOI 10.1007/s11060-008-9535-3
diseases, including Alzheimer’s [AD; 8–10] and Parkin-
son’s disease [PD; 11–13]. Oscillations are a feature of
neuronal brain activity and the synchronization of the
oscillatory activity (reflecting the interactions of neuronal
activity) is a likely mechanism for neuronal communication.
For an overview of the relation between oscillatory brain
activity and neurocognitive function [see 14, 15].
Magnetoencephalography (MEG) is a relatively novel
way to capture the dynamics of the electromagnetic fields
within the brain, and combines excellent temporal and
spatial resolution. Comparison of MEG in AD patients and
healthy controls showed more delta and theta activity in the
patient population especially in the temporo-parietal region
[16]. Another study compared spectral power in four dif-
ferent groups (severe AD, moderate AD, Lewy Body
dementia, and healthy controls) and showed that the heal-
thy control population had the largest rhythmic activity in
the alpha band. The moderate AD population and the
patients with Lewy Body dementia had the rhythmic pre-
dominance in the pre-alpha frequency band (7–9 Hz),
whereas the severe AD showed a shift towards the slow-
band (3–7 Hz) [17]. In PD patients, MEG has been used by
Kotini [18], who showed slowing of the alpha rhythm in
the patient population compared to healthy controls, and
Bosboom [19], who demonstrated slowing in the theta,
beta, and gamma frequency band in non-demented PD
patients with a further slowing (and involvement of delta
and alpha band) in the demented PD patient population.
It is suggested that the increase in slow wave activity
corresponds with neurocognitive deficits in AD as well as
in PD [13, 16, 19, 20].
MEG-studies have previously been performed in brain
tumor patients. Oshino [21] found an increase in delta and
theta band activity especially in the vicinity of the tumor
and in the surrounding regions of edema. In the majority of
these patients, the increase correlated with the clinical
symptoms of these patients, assessed with a routine neu-
rological examination, but neurocognitive function were
not formally investigated. Although the focal lesion in
brain tumor patients contrasts with the generalized brain
degeneration in AD and PD, there is evidence that brain
tumors can cause functional disturbances in areas remote
from the tumor [22–25]. De Jongh [22] found focal clusters
of delta activity near the tumor area but also in the con-
tralateral hemisphere. An evaluation of fast MEG waves in
brain tumor patients showed dipoles located in the parietal
and occipital area, whereas the tumors were located in the
parietal, temporal, and frontal area [23]. In this study, these
dipoles were found remote from the tumor area and even in
the contralateral hemisphere. Bartolomei [24, 25] found
differences in resting state functional connectivity in the
same brain tumor population within several frequency
bands when compared to healthy controls. Interestingly, in
agreement with de Jongh’s results, these differences were
not limited to the tumor area and were more obvious in
those with a tumor in the left hemisphere.
Since higher cognitive functions are presumed to depend
on the integrated activity of several specialized brain areas,
it is suggested that neurocognitive deficits may have a
stronger correlation with diffuse alterations in resting state
brain oscillatory activity than focal abnormalities in the
brain tumor population.
In the present MEG-study, power spectral analysis of
oscillatory brain activity was used to compare resting state
brain oscillatory activity in both LGG patients and healthy
controls.
We hypothesize that (1) LGG patients show, in addition
to the local abnormalities at the tumor site, global slowing
of the resting state brain activity compared to healthy
controls which will vary between patients with a tumor in
the left or right hemisphere (2) changes in resting state
brain oscillatory activity reflect an intermediate level
between the impact of tumor and tumor-related treatment
on the one hand (‘input’) and the neurocognitive deficits
(‘output’) on the other hand and that diffuse slowing is
correlated with higher neurocognitive dysfunction.
Materials and methods
Patients and controls
Twenty-three LGG patients were asked to participate in
this study. Patients were eligible if: (a) they had a sus-
pected or histologically confirmed LGG; (b) there was no
radiological (confirmed by MR or CT scan) and/or clinical
tumor progression in the previous 6 months; (c) they did
not use medication possibly interfering with neurocogni-
tive function, other than anti-epileptic drugs (AEDs).
Patients were recruited from the VU University Medical
Center (VUmc) and the Academic Medical Center (AMC),
both tertiary referral centres in Amsterdam for brain tumor
patients, after the institutional ethical review boards of both
participating hospitals approved the study protocol. Rela-
tives of the patients were asked to participate as healthy
controls. Healthy controls were eligible if they: (a) did not
suffer from any neurological disease; (b) did not use any
medication that might influence cognitive function. For
patients who could not provide a healthy control participant,
VU University Medical Center staff members were included.
Magnetoencephalography
MEG recordings were obtained using a 151-channel whole-
head MEG system (CTF systems; Port Coquitlam, British
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Columbia, Canada) while participants were seated inside a
magnetically shielded room (Vacuumschmelze GmbH,
Hanau, Germany). Magnetic fields were recorded during a
no-task, eyes-closed resting state. Metal artefacts were
avoided as much as possible. A third-order software gra-
dient [26] was used with a recording passband of 0.25–
125 Hz and a sample frequency of 312.5 Hz. At the
beginning, middle and end of each recording, the head
position relative to the coordinate system of the helmet was
recorded by leading small alternating currents through
three head position coils attached to the left and right
preauricular points and the nasion on the subject’s head.
Head position changes up to approximately 1.5 cm during
a recording condition were accepted.
For this study, 149 of the 151 channels could be used.
MEG recordings were converted to ASCII files. From these
ASCII files four artefact free epochs of 13 s per subject
(4096 samples) were carefully selected by visual analysis
by one of the authors (IB).
Magnetic field frequencies ranging from 0.5 to 80 Hz
were recorded. The MEG data were digitally filtered off-
line in the following frequency bands: delta (0.5–4 Hz),
theta (4–8 Hz), lower alpha (8–10 Hz), upper alpha (10–
13 Hz), beta (13–30 Hz), gamma (30–50 Hz).
The MEG channels were grouped into 10 distinct
regions, respectively left and right frontal region, left and
right temporal region, left and right parietal region, left and
right occipital region and left and right central region, as
shown in Fig. 1. Fast Fourier transformation was separately
applied for every patient and control on the four epochs in
the above mentioned frequency bands. The results of the
four epochs were averaged for each participant and the
mean relative power for each MEG region were used for
the analysis.
Neurocognitive assessment
Patients and controls participated in neurocognitive
assessment (see Table 1). The total duration of the
assessment varied between 1 and 2 h. Individual patient’s
test scores were converted to z-scores, using the means and
standard deviations of the age-, sex- and education-mat-
ched healthy controls as a reference.
To reduce data, individual scores on these tests were
summarized into six cognitive domains, namely informa-
tion processing speed, psychomotor function, attention,
verbal memory, working memory, and executive func-
tioning. Construction of these domains has previously been
reported [30], and was based on a Principal Component
Analysis using Varimax rotation with Kaiser normalization
performed on the z-scores of a large group of healthy
controls [31]. The domains found are commonly used in
neurocognitive practice and research.
Statistical analysis
Differences between both groups in the distribution of age,
sex, and education were analyzed by means of chi-square
tests. Mann–Whitney nonparametric U-tests were used to
investigate whether patients’ standardised z-scores on
neurocognitive tests in the overall measure of cognition
differed significantly from healthy control z-scores.
Because of the non-normal distribution of the relative
power, Mann–Whitney nonparametric U-tests were used to
determine possible differences between the patient popu-
lation and healthy controls.
To assess the association between relative power and
cognition within the patient group, Spearman’s correla-
tion coefficient (q) was calculated between the relative
power in the different MEG regions and z-scores of the
six neurocognitive domains for all separate frequency
bands.
Results
Patient characteristics
From the initial patient group, six patients were excluded,
four patients due to metal artefacts on the MEG measure-
ments, one due to severe epileptic seizures, and one due to
tumor progression at the time of registration. The finalFig. 1 Distribution of MEG regions
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analyses were performed on a sample of 17 patients and 17
matched healthy control participants.
Due to the matching procedure, there were no significant
differences between patients and healthy controls in age
(M = 42.7, SD = 11.2 in patients, M = 42.6, SD = 12.7
in healthy controls, p = 0.99), and educational level
(M = 5.2, SD = 1.8 in patients, M = 5.5, SD = 1.8 in
healthy controls, p = 0.64). The male–female ratio
between the two groups did not differ significantly
(p = 0.37). Fourteen of the 17 LGG patients had a histo-
logically confirmed LGG, clinically and radiologically
stable for more than six months before inclusion, whereas
the other 3 patients were suspected of having LGG, and
stable for more than six months. The patients in our study
were diagnosed several years ago (mean 8 years, range:
1–19 years). One year after MEG registration two of the
three patients with suspected LGG were operated on
because of increasing epilepsy frequency.
Eleven of those 16 patients underwent debulking,
whereas 3 patients underwent a stereotactic biopsy and
another two patients had an open biopsy. Of the 16 patients
with a histologically confirmed LGG, the pathological
diagnosis was grade II astrocytoma in ten patients, oligo-
dendroglioma grade II in four patients and oligoastrocytoma
grade II in two patients.
Seven of the seventeen patients underwent radiotherapy
with prior chemotherapy in two patients (1 patient with 5
cycles of PCV and 1 patient with 2 cycles of PCV and 3
cycles of temozolomide). Eleven patients had left hemi-
sphere tumors and 6 patients had right-sided tumors. The
specific localisation of the tumor is shown in Table 2.
In the patient group, all but one patient used AED mono-
or poly-therapy. Six of the 16 patients on AED were free of
seizures, while the other 10 patients were still having
seizures.
Differences between patient and healthy control group
Neurocognitive functioning
As expected, patients performed poorer than healthy controls
on the neurocognitive test battery (controls M = 0.00).
More specifically, patients showed a significantly lower
psychomotor function (M = -0.50, SD = 0.75 versus
SD = 0.55, p = 0.044), working memory capacity (M =
-1.43, SD = 1.62 versus SD = 0.91, p = 0.002), infor-
mation processing speed (M = -0.85, SD = 0.88 versus
SD = 0.97, p = 0.018) and attention (M = -1.92, SD =
3.87 versus SD = 0.68, p = 0.003). Patients’ performance
on the other two cognitive domains did not differ signifi-
cantly from controls (Fig. 2).
Spectral analysis
Global spectral analysis. The mean relative power of the
LGG patient population showed a significant decrease
(Mann–Whitney U, p = 0.034) in the gamma band (30–
50 Hz) compared with healthy controls.
Table 1 Description of neuropsychological test battery
Letter-digit substitution
test [27]
This test provides a measure of psychomotor performance that is relatively unaffected by intellectual prowess and is
suitable for groups with an age range exceeding 60 years. The number of items written down in 90 s is registered,
as in the decrease in performance when graphomotor speed is involved
Visual verbal learning test
[27]
This version of the Rey Auditory Verbal Learning Test calls for various aspects of verbal learning and recall.
Measures used for analysis are memory performance on trial 1 as indicator of immediate recall, total recall after
five trials, delayed recall and recognition after 20 min as indicators of memory consolidation into long-term
memory, and a delta score as a measure of learning capacity
Stroop color-word test
[27]
This test is a selective attention task aiming at measuring interference susceptibility and consists of three subtasks
with increasing task complexity
Categoric word fluency
[28]
A simple task requiring the generation of words from semantic categories (animals) within a limited time
Concept shifting test [29] This test, which has two conditions of complexity, predominately measures functions associated with executive
function, especially visual scanning and conceptual tracking. The motor component of this task is measured by
three dummy conditions in which no cognitive capacity except for graphomotor speed is required
Memory comparison test
(MCT)
Selective attention, mental concentration, memory and information processing
Table 2 Tumor lateralization and localization
Left hemisphere Right hemisphere
Tumor location No. of
patients
Tumor location No. of
patients
Left frontal 4 Right frontal 2
Left parietal 3 Right frontoparietal 3
Left temporal 3 Right insular region 1
Left parieto-occipital 1
Total 11 Total 6
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Spectral analysis of frequency bands within each MEG
region. An increase (Mann–Whitney U; p = 0.014) in
relative power in the LGG patients compared to the healthy
controls was found in the left parietal region within the
theta frequency band (4–8 Hz). A decrease in relative
power was seen in the left and right central region (Mann–
Whitney U; both p = 0.024) and left and right frontal
region (Mann–Whitney U; both p = 0.005) of the LGG
patient population compared to the healthy controls within
the gamma band (30–50 Hz), as shown in Table 3 and
Fig. 3.
Influence of tumor lateralization on relative power.
Eleven patients had left hemisphere tumors and 6 patients
had a tumor in the right hemisphere. Patients with a tumor
in the left hemisphere showed an increase in theta activity
in the left and right central region (Mann–Whitney U;
respectively p = 0.001 and p = 0.014), left and right
parietal region (respectively p = 0.004 and p = 0.029),
and left and right temporal region (respectively p = 0.022
and p = 0.027) when compared to the healthy control
population. Patients with left-sided tumors also showed a
decrease in relative power in the gamma band in the left
and right central region (respectively p = 0.023 and
p = 0.048) and left and right frontal region (respectively
p = 0.011 and p = 0.019).
Patients with a tumor in the right hemisphere showed a
significant increase in relative power of delta activity in the
right parietal region (Mann–Whitney U; p = 0.050) com-
pared to the healthy control population. These patients also
showed a decrease in relative power in the gamma band in
the left and right frontal region (respectively p = 0.005 and
p = 0.025), right temporal region (p = 0.042), and left and
right occipital region (respectively p = 0.025 and
p = 0.014), as shown in Table 4 and Fig. 4.
Since these results could be influenced by differences in
tumor volume, we evaluated the tumor size of participating
patients. We used T1-weigthed MRI and defined tumor size
as the product of the two largest perpendicular diameters of
tumor hypointensity [32]. We found no significant differ-
ences in the tumor size between left- and right-sided
tumors.
Associations between patient’s neurocognitive
functioning and relative power in distinct MEG regions
In the patient population, negative associations between
neurocognitive functioning and relative power were found
in the theta and lower alpha band. An increase in the rel-
ative power in the theta band within the left frontal
(-0.606; p = 0.010) and the right frontal region (-0.490;
p = 0.046) was correlated with a poorer executive func-
tioning. In the same frequency band (4–8 Hz), an increase
in theta band power was correlated with poorer information
processing within the left central and left frontal region
(respectively -0.515; p = 0.034 and -0.592; p = 0.012).
Within the lower alpha band in the right temporal region,
an increase in relative power was correlated with a dis-
turbed working memory (-0.508; p = 0.037).
Discussion
The primary goal of the present study was to evaluate
whether LGG patients show (in addition to the well known
MEG slowing around the tumor) diffuse slowing in resting
state brain activity. The secondary goal of the study was to
investigate whether this slowing is correlated with neuro-
cognitive dysfunction. By means of MEG-registrations we
have demonstrated that LGG patients have slowing of the
Fig. 2 Patients’ z-scores on the six neurocognitive domains and on
total neurocognitive functioning. Note: * p \ 0.05, ** p \ 0.01.
A = attention, EF = executive functioning, IPS = information pro-
cessing speed, PF = psychomotor function, VM = verbal memory,
WM = working memory. Performance is relative to that of age-, sex-,
and education-matched healthy controls (represented by the 0-line). A
higher score (i.e. approaching 0) means better performance
Table 3 Significant differences in relative power between patients
and controls per frequency band and accompanying statistics
Patients Controls p
M SD M SD
Theta Left parietal 0.131 0.053 0.092 0.026 0.014
Gamma Left central 0.064 0.027 0.095 0.041 0.024
Right central 0.066 0.033 0.102 0.047 0.024
Left frontal 0.048 0.027 0.088 0.043 0.005
Right frontal 0.050 0.030 0.083 0.037 0.005
Significant higher relative power is depicted in bold and in italics
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resting state brain activity when compared to healthy
controls. The decrease in relative power was mainly found
in the gamma frequency band in the bilateral frontocentral
MEG regions. Regarding the low frequency bands, an
increase in relative power was found in the theta frequency
band in the left parietal region. Correlations of
Fig. 3 The significant
differences in relative power
between the patient group and
the healthy controls within the
different frequency bands.
Green area: significant higher
relative power in the patient
group compared to the healthy
controls. Red area: significant
lower relative power in the
patient group compared to the
healthy controls
Table 4 Significant differences
in relative power between
patients with a tumor in the left
or right hemisphere and controls
per frequency band and
accompanying statistics
Significant higher relative
power is depicted in bold and in
italics
Patients Controls p
M SD M SD
Left hemisphere Theta Left central 0.141 0.039 0.095 0.018 0.001
Right central 0.133 0.041 0.096 0.022 0.014
Left parietal 0.149 0.057 0.092 0.026 0.004
Right parietal 0.141 0.065 0.089 0.029 0.029
Left temporal 0.107 0.049 0.072 0.019 0.022
Right temporal 0.100 0.043 0.071 0.023 0.027
Gamma Left central 0.063 0.026 0.095 0.041 0.023
Right central 0.069 0.032 0.102 0.047 0.048
Left frontal 0.048 0.027 0.088 0.043 0.011
Right frontal 0.053 0.031 0.083 0.037 0.019
Right hemisphere Delta Right parietal 0.424 0.144 0.303 0.137 0.050
Gamma Left frontal 0.050 0.028 0.088 0.043 0.005
Right frontal 0.045 0.031 0.083 0.037 0.025
Right temporal 0.042 0.022 0.070 0.045 0.042
Left occipital 0.040 0.029 0.077 0.032 0.025
Right occipital 0.048 0.036 0.099 0.037 0.014
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neurocognitive functioning with the relative power in the
patient population showed clear associations in the lower
alpha and theta band, increased slowing correlating with
poorer performance.
We chose to use the relative power instead of the
absolute power, because relative power is less influenced
by the distance between the MEG sensor and the under-
lying neural populations. The distance is variable due to
head position in the helmet and the thickness of the skull.
Lower variance of power values in subject groups are
expected by using the relative power instead of the absolute
power. A second reason for us to use this method is the fact
that by using this method we are able to compare our
results with those of other patient cohorts at our MEG
center [19, 20]. This includes comparisons with other brain
tumor data sets but also the comparison of our results with
neurodegenerative diseases (including AD and Parkinson’s
disease (PD)). This will give us an opportunity to learn
more about differences in resting state oscillatory brain
activity in the different diseases and at different disease
stages. A limitation of this method of analysis is that an
increase in one frequency band can cause a decrease in
another band, although this might not be the observed
pattern in absolute measures.
In previous studies, MEG has been used for power
analysis in patients with neurodegenerative diseases, such
as AD and PD. They showed similar results, namely a
rhythmic predominance in the lower frequency bands, as
was found in our study with LGG patients [16–20]. There
are only few studies performed in brain tumor patients,
however.
De Jongh [22] demonstrated that both a higher tumor
malignancy and larger tumor volume were associated with
higher signal powers in the delta band. In our study, we did
not find increased oscillatory brain activity in the delta
band. It might be that the conflicting results are due to
differences in methodology of both studies. In contrast with
De Jongh’s study [22], we analysed the relative power,
which means that the power is influenced by the power in
the other frequency bands and therefore group differences
in a specific frequency band could results from changes in
that specific band or in the absolute power of the other
frequency bands. Furthermore, we evaluated diffuse delta
activity instead of clusters of dipoles in the vicinity of the
tumor. Apart from these technical differences, De Jongh’s
patient population consisted of a more heterogeneous
group of brain tumor patients. They found a higher delta
power in the high-grade gliomas compared to those
patients with a low-grade glioma and a delta signal power
decrease after surgery. Our patient population consisted
exclusively of patients with a low-grade glioma, and all but
three MEG registrations were done after surgery, which
might explain the lack of changes in the delta band in the
present study. It also suggests that changes in the gamma
and theta band may be more sensitive indicators of brain
dysfunction in LGG.
In another study of De Jongh [23], the authors found
focal clusters of fast MEG waves outside the tumor area
and even in the contralateral hemisphere. They concluded
that the asymmetry possibly reflects features of normal
background activity, since asymmetry has already been
demonstrated in healthy subjects for the alpha activity
which is usually dominant in the right hemisphere. Since
De Jongh used a single dipole analysis instead of our
analysis of diffuse power changes and, again, analysed a
group of patients with diverse brain tumors, it is difficult to
compare the results of both studies.
Oshino and colleagues [21] used synthetic aperture
magnetometry (SAM) to analyze oscillatory activity
recorded by the MEG. SAM is an alternative method
investigating the distribution of reconstructed sources over
different cortical regions. In contrast to other source
Fig. 4 The significant
differences in relative power
between the patients with a
tumor in the left or right
hemisphere compared to the
healthy controls within the
different frequency bands.
Green area: significant higher
relative power in the patient
group compared to the healthy
controls. Red area: significant
lower relative power in the
patient group compared to the
healthy controls
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localization methods, beamforming does not rely on aver-
aging and therefore allows analysis of evoked and induced
brain activity. In a group of 15 patients with various types
of primary or secondary brain tumors, they found an
increase in delta and theta band activity especially in the
vicinity of the tumor and in the surrounding regions of
edema. In the majority of these patients, the increase in the
delta band correlated well with the clinical symptoms,
assessed with a routine neurological examination. The
results were not correlated with neurocognitive functioning
because they stated that there is much individual variation
in brain activity related to neurocognitive function and they
expected it difficult and sometimes impossible for these
patients to undergo the neurocognitive battery. In contrast
to their results, we only found an increase in theta activity
and decrease in the gamma frequency band. As mentioned
before we analyzed the relative power and also our patient
population with only LGG patients is not comparable to the
patients with various brain tumors in the study of Oshino.
Although, different methods to reconstruct sources can
show significant discrepancies, we also found spectral
changes in the contralateral hemisphere.
By evaluating separately those patients with a tumor
localisation in the left or the right hemisphere, we found more
significant differences in patients with a tumor in the left
hemisphere compared to healthy controls. In agreement with
our previous study [24], in which we evaluated the functional
connectivity (functional connectivity is a statistical correla-
tion between time series of brain activity recorded over
distinct regions which are assumed to reflect interactions
between the brain regions) in patients with diverse primary
brain tumors, we also found that patients with a tumor in the
left hemisphere showed more differences in this functional
connectivity compared to those with right-sided tumors.
Why those patients with a tumor in the left hemisphere
do show more differences in oscillatory activity is not
known. It is possible that the left hemisphere (usual the
dominant hemisphere) acts differently to the tumor com-
pared to those located in the right hemisphere. It is also
possible that patients with a tumor in the left hemisphere
are in a different stage of their disease compared to those
with a tumor in the right hemisphere. Since our sample size
is rather small, this could be reflected on the observed
results. On the other hand is it possible that our results
reflect hemispheric asymmetry which has been found in the
healthy population previously. Gootjes et al. [33] found
hemispheric differences in functional connectivity in
healthy young adults during resting state.
The neurocognitive domains of psychomotor function,
working memory, information processing speed and atten-
tional tasks were impaired in LGG patients. These results
corroborate previous studies indicating a decline in neuro-
cognitive functioning in LGG patients [6, 34–38]. Several
research groups have suggested that the increase in slow wave
activity corresponds with neurocognitive deficits in AD and
PD. Fernandez [16] found right parietal delta activity to be
significantly associated with variability in the Cambridge
Examination for Mental Disorders in the elderly (CAMCOG)
score, whereas the left temporal theta activity predicted the
variability of Mini Mental State Examination (MMSE)
results. Sinanovic [13] found a positive correlation between
diffuse changes in spectral power and MMSE scores in the PD
patients with dementia. Bosboom [19] found a negative cor-
relation in the non-demented PD patients between theta power
and CAMCOG scores in both occipital and right temporal
region but expected these associations, given the large number
of relations that were analyzed, likely to be caused by coin-
cidence. In the demented PD group they found no significant
correlations. Stoffers [20] showed a negative association
between lower alpha power and the performance on persev-
eration-related tasks in the non-demented PD patients.
Evidently, this study has its limitations. First of all, the
patient group is rather small as mentioned before. Sec-
ondly, although our patient population consisted of only
LGG patients, they did not all receive the same treatment.
In our study we hypothesized changes in oscillatory brain
activity to be the intermediate between the impact of the
tumor and its treatment on the one hand and the neuro-
cognitive deficits as the output on the other hand. This
study showed that irrespective of the different treatment
options, changes in oscillatory brain activity can be found
in brain tumor patients which is associated with neuro-
cognitive function. To get informed on the influence of the
different tumor treatments on brain activity and its relation
with neurocognitive function is very interesting. A longi-
tudinal study of these effects (e.g. surgery, radiotherapy
and chemotherapy) on brain activity is currently under
way. The goal of that study is to explore correlations
between changes in neurocognitive function and changes in
functional brain dynamics during the disease course.
Our study is the first to correlate the relative power with
neurocognitive functioning in brain tumor patients. The
observed correlations were quite strong and showed that an
increased activity in the theta and lower alpha band is
correlated with impaired executive functioning, informa-
tion processing and working memory. This is a first step in
unraveling the underlying mechanisms of neurocognitive
dysfunction in brain tumor patients. MEG power analysis
gives us an interesting tool to assess functional alterations
in the patient’s brain in the course of disease and to eval-
uate its relationship with neurocognitive functioning.
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